It has been reported that tumor‐draining lymph node (TDLN)‐derived tumor‐specific memory T cells are the primary responders to PD‐1/PD‐L1 ICB.[45] Furthermore, PD‐1/PD‐L1 blockade preferentially expands precursor‐exhausted T cells rather than terminally exhausted T cells.[22] Our results indicate that CXCL13‐overexpression enhances the central memory phenotype of CAR T cells and reduces exhaustion, enabling them to respond more effectively to PD‐1 blockade. The gene discussed is CXCL13; the disease is neoplasm.